ClinicalTrials.gg
RecruitingNCT07492927Updated Mar 25, 2026

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

An observational study in Clinically Significant Prostate Cancer, sponsored by Xijing Hospital. Recruiting at 10 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Xijing Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,700
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Prostatic Neoplasms by Xijing Hospital — 10 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · Xijing Hospital.

Started
2021
with 4 others
Observational
6 of 10
6 open now
Registered
10th of 10
by date

Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, this one is one of 5 that started in 2021, is one of 6 observational ones, and was the 10th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 10 studies in Prostatic Neoplasms by Xijing Hospital are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms by Xijing Hospital, or all of them as a file.
02

Study summary

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

03

Conditions studied

  • Clinically Significant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The men with suspected prostate cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Blood prostate-specific antigen PSA>4ng/dl;
  2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
  3. The patient is willing to undergo prostate .

Exclusion criteria

Exclusion Criteria:

  1. Previous diagnosis of prostate cancer through prostate ;
  2. History of other malignant tumors in the past two years;
  3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,700 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study Cohort

    The experimental arm receiving diagnosis from serum RNA combination

06

What researchers measure

Primary outcomes

  1. The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing csPCa

    The primary outcome is to investigate a plasma-exosome RNA panel in diagnosing clinically significant prostate cancer (csPCa) and evaluate its sensitivity and specificity in diagnosing csPCa. Descriptive statistics were calculated and presented as the frequency (percentage) for categorical variables, the mean (standard deviation) for continuous variables with a normal distribution, and the median (quartile) for continuous variables with a skewed distribution. Two-sample t-tests were used to assess continuous variables with a normal distribution, and the Wilcoxon signed-rank test was used to assess continuous variables with a skewed distribution. The Mann-Whitney U test was used to compare means from two samples. The correlation between two samples was analyzed by Spearman's ρ test. The receiver operating characteristic (ROC) curve was used to determine the cutoff value of exo-RNA panel for diagnosing patients with csPCa.

    Time frame: The time of prostate biopsy

Secondary outcomes

  1. Diagnostic efficacy of plasma exo-RNA panel in diagnosing csPCa and its comparison with other imaging methods or blood tests

    The secondary outcome is to evaluate the positive predictive value (PPV), negative predictive value (NPV) and accuracy of exo-RNA panel in detection of csPCa; and compare the diagnostic performance of the plasma-exosome RNA panel with other imaging methods or blood tests in identifying prostate cancer patients; Whether the exo-RNA panel could predict the PCa patients with higher Gleason score (GS). The comparison between diagnostic performance of exo-RNA panel and other imaging or blood tests is performed in ROC curves. The ICC analysis was performed by reliability analysis. All statistical analyses were conducted using IBM SPSS statistics software, version 23.0 (IBM, Inc., Chicago, IL, USA) and GraphPad Prism software, version 8.0 (GraphPad Software, Inc., La Jolla, CA, USA).

    Time frame: The time of prostate biopsy

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 69 months is close to that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 25, 2026
StartActual
Mar 12, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07492927
Lead sponsor
Xijing Hospital
Collaborators
Shaanxi Provincial People's Hospital, Weinan Central Hospital, Shaanxi University of Chinese Medicine, LanZhou University, Qinghai University, Ningxia Medical University, Northwestern University, Yan'an University Affiliated Hospital, Air Force Military Medical University, China
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Mar 12, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 25, 2026

Study contacts

Jianhua Jiao, MD.
Contact
1531769428@qq.com
+86 029 84771062
Weijun Qin, MD.
study chair · Xijing Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion